Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 208

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Chronic Myelogenous Leukemia

Open access
O'Brien, Susan, Berman, Ellin, Borghaei, Hossein, DeAngelo, Daniel J., Devetten, Marcel P., Devine, Steven, Erba, Harry P., Gotlib, Jason, Jagasia, Madan, Moore, Joseph O., Mughal, Tariq, Pinilla-Ibarz, Javier, Radich, Jerald P., Shah, Neil P., Shami, Paul J., Smith, B. Douglas, Snyder, David S., Tallman, Martin S., Talpaz, Moshe, Wetzler, Meir·2009·Journal of the National Comprehensive Cancer Network

Abstract

Chronic Myelogenous Leukemia Version 2:2010Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial.Participation in clinical trials is especially encouraged.All recommendations are category 2A unless otherwise noted.WORKUP a Chronic phase adult CML Ph negative and BCR-ABL negative 1 Ph positive or BCR-ABL positive 1 H&P CBC, platelets Chemistry profile Consider HLA testing Bone marrow aspirate and biopsy Morphologic review Percent blasts Percent basophils Cytogenetics, FISH, QPCR b c Evaluate for other diseases (not CML) Discussion of treatment options including: Imatinib Role of HSCT Clinical trial d,e f,g Imatinib, 400 mg (category 1) h,i,j PRIMARY TREATMENT a See Monitoring for Patients Receiving Tyrosine Kinase Inhibitor therapy (page 992).c See text for further discussion regarding the role of FISH in the initial workup of patients with CML.d There is 7 year follow-up data which shows clear evidence of excellent survival benefit with imatinib.See text for additional information.e For patients with symptomatic leukocytosis or thrombocytosis, see Supportive Care Strategies (page 992).f HSCT = hematopoietic stem cell transplantation.Refers to a matched related and unrelated allogeneic transplant.HLA testing should be performed if considering HSCT.g Indications and outcomes of related and unrelated transplant are age, donor type, and transplant center dependent.Nonmyeloablative transplant is under investigation and should be performed only in the context of a clinical trial.h There are data suggesting a faster time to MMR with a higher dose of imatinib but whether this is an important end point in long-term outcome is unknown.Cortes J, Baccarani M, Guilhot F, et al.A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular endpoints: 1 year results of TOPS study [abstract].Blood 2008;112:Abstract 335.i See Management of Imatinib Toxicity (page 993).j Rare patients unable to tolerate imatinib, dasatinib, or nilotinib should consider IFN/PEG-IFN or clinical trial.b Bone marrow is preferable for the initial workup, not only to provide morphologic review, but also to detect chromosomal abnormalities that are not detectable on peripheral blood FISH.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.6004/jnccn.2009.0065

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 208

Metadata

Authors
O'Brien, S., Berman, E., Borghaei, H., DeAngelo, D. J., Devetten, M. P., Devine, S., Erba, H. P., Gotlib, J., Jagasia, M., Moore, J. O., Mughal, T., Pinilla-Ibarz, J., Radich, J. P., Shah, N. P., Shami, P. J., Smith, B. D., Snyder, D. S., Tallman, M. S., Talpaz, M., & Wetzler, M.
Venue
Journal of the National Comprehensive Cancer Network
Published
2009-10
Volume
7
Issue
9
Pages
984-1023
ISSN
  • 1540-1405 (ISSN-L)
  • 1540-1413
OpenAlex
W3027130291
Cited by
208
References
4
FWCI
13.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chronic Myelogenous Leukemia. https://app.cochat.ai/papers/10.6004/jnccn.2009.0065
The paper
O'Brien, S., Berman, E., Borghaei, H., DeAngelo, D. J., Devetten, M. P., Devine, S., Erba, H. P., Gotlib, J., Jagasia, M., Moore, J. O., Mughal, T., Pinilla-Ibarz, J., Radich, J. P., Shah, N. P., Shami, P. J., Smith, B. D., Snyder, D. S., Tallman, M. S., Talpaz, M., & Wetzler, M. (2009). Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2009.0065

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.